Back to search results

Phase 2 Delgocitinib Cream for Frontal Fibrosing Alopecia

This is a Phase 2 research study testing a cream called delgocitinib (20 mg/g) for people with Frontal Fibrosing Alopecia (FFA). FFA is a condition that causes hair loss. The study aims to see how safe and effective delgocitinib cream is in treating FFA. Everyone in this study will receive the delgocitinib cream. Researchers will measure changes in your hairline over 24 weeks to see if the treatment is working. You can join if you are 18 years or older. The study plans to enroll 30 participants, but its current recruitment status is unclear.

Study design
This is an open-label Phase 2 study, meaning you and the researchers will know you are receiving delgocitinib cream. It plans to enroll 30 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your hairline will be measured for up to 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07671157

Phase 2 Open Label Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)

Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatment
Maryanne Makredes Senna
~30 participants
Updated 2026-06-26 on ClinicalTrials.gov
What's tested:Delgocitinib

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Hairline measurements
Measured over from 0 to 24 weeks

Conditions

Frontal Fibrosing Alopecia

Explore related trials

Frontal fibrosing alopecia

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

Maryanne Senna, MD
[email protected]
7817441375
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any trial-related procedures.
Subjects must be willing to comply with all trial procedures and must be available for the duration of the trial.
Male or female subject aged 18 years of age or older at the time of consent.
Female subject of childbearing potential has had a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1.
Subject has clinically confirmed diagnosis of FFA based on investigator judgment.
Subject has a target area with moderate to severe perifollicular erythema and/or scale at Screening and Day 1.
For subject who uses make-up, moisturizers, creams, lotions, cleansers, and/or sunscreens on the face, subject has used the same product brands/types for a minimum period of 4 weeks prior to Day 1, agrees not to change brand/type or frequency of use throughout the trial, agrees not to apply those products on the treated area during the trial, and agrees not to use make-up, moisturizers, creams, lotions, cleansers, and/or sunscreens on the face on the clinic visit days before the visit.
Subject is willing to maintain a consistent hair style and hair style regimen, including shampoo and hair products (including hair dye, process, and timing to hair appointments), and to refrain from weaves or extensions throughout the course of the trial and for 4 weeks prior to Day 1. Note: Hair dying and shaving of scalp is allowed during the trial but not within 48 hours prior to a trial visit.

What this trial measures

  • Hairline measurementsfrom 0 to 24 weeks

    Change in hairline measurements from baseline to Week 24. (ie, lateral canthus \[right and left\] to hairline, lower glabellar crease to hair line, top of frontalis muscle to hair line, and mid brow to hair line \[right and left\])